What is Shift Labs?
Shift Labs operates at the intersection of medical device innovation and patient safety, primarily through its flagship DripAssist Infusion Rate Monitoring Platform. As the first FDA-cleared monitor specifically engineered for gravity IV infusions, the company addresses a critical gap in healthcare delivery by providing a cost-effective, accurate alternative to traditional, high-cost infusion pumps. By facilitating precise medication administration in home care, veterinary, and public health environments, Shift Labs has established a unique market position that prioritizes both clinical efficacy and operational efficiency for healthcare providers.
How much funding has Shift Labs raised?
Shift Labs has raised a total of $1.3M across 2 funding rounds:
Unspecified
$1.2M
Debt
$96K
Unspecified (2015): $1.2M, investors not publicly disclosed
Debt (2021): $96K led by PPP
Key Investors in Shift Labs
PPP
Public-Private Partnership
Undisclosed Investor
A private capital source that participated in the early-stage development of the company's core infusion monitoring technology.
What's next for Shift Labs?
With the recent injection of capital, Shift Labs is poised to scale its commercial operations and deepen its penetration into the home care market. The strategic focus will likely shift toward expanding the adoption of the DripAssist platform, leveraging its value proposition of reducing overhead costs while maintaining high standards of patient safety. As the company matures, further investment in product iteration and market education will be essential to solidify its role as a standard-bearer for affordable, high-precision infusion therapy, potentially setting the stage for future enterprise-level growth and broader clinical integration.
See full Shift Labs company page
